Barclays PLC Boosts Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Barclays PLC raised its holdings in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 243.6% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 59,502 shares of the company’s stock after acquiring an additional 42,185 shares during the period. Barclays PLC’s holdings in ALX Oncology were worth $107,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after buying an additional 5,200 shares during the period. Hsbc Holdings PLC purchased a new stake in ALX Oncology during the second quarter valued at about $63,000. AQR Capital Management LLC boosted its position in ALX Oncology by 50.7% during the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock valued at $109,000 after buying an additional 6,080 shares during the period. SG Americas Securities LLC boosted its position in ALX Oncology by 33.6% during the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after buying an additional 6,888 shares during the period. Finally, Algert Global LLC purchased a new stake in ALX Oncology during the second quarter valued at about $249,000. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at ALX Oncology

In other news, Director Rekha Hemrajani purchased 30,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were purchased at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the completion of the acquisition, the director now directly owns 33,000 shares in the company, valued at $51,150. This represents a 1,000.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders sold 14,443 shares of company stock valued at $23,309. Corporate insiders own 33.40% of the company’s stock.

ALX Oncology Price Performance

Shares of NASDAQ ALXO opened at $1.85 on Thursday. ALX Oncology Holdings Inc. has a fifty-two week low of $1.19 and a fifty-two week high of $17.83. The company has a 50 day simple moving average of $1.56 and a two-hundred day simple moving average of $2.72. The company has a market capitalization of $97.57 million, a price-to-earnings ratio of -0.62 and a beta of 0.98. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ALXO. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research note on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research note on Wednesday, December 18th. Finally, Jefferies Financial Group downgraded shares of ALX Oncology from a “buy” rating to a “hold” rating and lowered their price objective for the company from $12.00 to $2.00 in a research note on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, ALX Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.